Recursion Pharmaceuticals RXRX, a TechBio company that decodes biology and chemistry to industrialize drug discovery, is expected to report fourth-quarter 2025 results soon. The Zacks Consensus ...

Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings.

Monday evening, the hydrogen technology company reported an adjusted per-share loss of 6 cents from sales of $225.2 million. Wall Street was looking for a 10-cent loss from sales of $217 million.